Расширенный поиск

Безопасность комбинированной терапии сальметеролом и флутиказона пропионатом у больных бронхиальной астмой

Полный текст:

Ключевые слова

УДК 616.248-085.234

Об авторах

А. В. Емельянов
Санкт-Петербургская медицинская академия последипломного образования

Г. Р. Сергеева
Санкт-Петербургская медицинская академия последипломного образования

Список литературы

1. Global initiative for аsthma. - NHLB / WHO Workshop Report.-National Heart Lung Blood Institute, Publication number 02-3659, revised 2006: Пер. с англ. под ред. А.Г.Чучалина. М.: Атмосфера; 2007.

2. Pauwells R.A., Lofdahl C-G., Postma D. et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N. Engl. J. Med. 1997; 337 (20): 1412-1418.

3. Bateman E.D., Boushley H.A., Bousquet J. et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control Study. Am. J. Respir. Crit. Care Med. 2004; 170: 836-844.

4. Castle W., Fuller R., Hall J., Palmer J. Serevent nationwide surveillance study:comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. Br. Med. J. 1993; 306: 1034-1037.

5. Nelson H.S., Weiss S.T., Bleecker E.R. et al. The salmeterol multicenter asthma research trial (SMART): а comparisan of usual pharmacotherapy for asthma ог usual pharmacotherapy рlus salmeterol. Chest 2006; 129 (1): 15-26.

6. Barnes P. Beta-adrenergic receptors and their regulation. Am. J. Respir. Crit. Care Med. 1995; 152 (3): 838-860.

7. Oppenheimer J., Nelson H.S. Safety of long-acting β-agonists in asthma: а review. Curr. Opin. Рulm. Med. 2008; 14 (1): 64-69.

8. Bleecker E.R., Postma D.S., Lаwranсе R.M. et al. Effect of АDRВ2 рolymorphisms on response to long-acting beta2-agonist therapy: а pharmacogenetic analysis of two randomized studies. Lancet 2008; 370 (9605): 2118-2125.

9. Bleecker E.R., Yаnсеу S.W., Baitinger L.A. et al. Salmeterol response is not affected bу beta2-adrenergic receptor gеnotуре in subjects with persistent asthma. J. Allergy Clin. Immunol. 2006; 118 (4): 809-816.

10. Sindi А., Todd D.C., Nair P. Antiinflammatory effects of long-acting beta2-agonists in patients with asthma. A systematic review and metaanalysis. Chest 2009; 136 (1): 145-154.

11. Parameswaran K., Fanat A., O'Byrne P.M. Effect of intranasal fluticasone and salmeterol on allergen-induced nasal responces. Allergy 2006; 61 (6): 731-736.

12. Derendorf H. Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. Respir. Med.1997; 91 (suppl. A): 22-28.

13. Adams N., Bestall J., Lasserson T. et al. Inhaled fluticasone versus inhaled beclomethasone or inhaled budesonide for chronic asthma. Cochrane Database Syst. Rev. 2004; 2: CD002310.

14. Irwin R.S., Richardson N.D. Side effects with inhaled corticosteroids. Chest 2006; 130 (1, suppl.): 41S-53S.

15. Shuto Н., Nagata М., Terashi У. et аl. Esophageal candidiasis as complication оf inhaled steroid therapy. Arerugi 2003; 52: 1053-1064.

16. Spencer С.М., Jarvis В. Salmeterol / fluticasone propionate combination. Drugs I999; 57: 933-940.

17. Lipworth B.J., Jackson C.M. Safety of inhaled and intranasal corticosteroids: lessons for new millennium. Drug Saf. 2000; 23 (1): 11-33.

18. Busse W., Koenig S.M., Oppеnheimer J. et аl. Steroid sparing effects of fluticasone 100 μg and salmeterol 50 μg administered twice daily in а singlе рrоduсt in patients previously controlled with fluticasone 254 μg twice daily. J. Allergy Сlin. Immunol. 2003; 111 (1): 57-85.

19. Bailey W., Castro M., Matz J. et al. Asthma exacerbations in African Americans treated for 1 year with combination fluticasone propionate and salmeterol or fluticasone propionate alone. Curr. Med. Res. Opin. 2008; 24 (6): 1669-1682.

20. Ni Chroinin M., Greenstone I.R., Danish A. et al. Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma. Cochrane Datbase Syst. Rev. 2005; 4: CD005535.

21. Greenstone I.R., Ni Chroinin M.N., Masse V. et al. Combination of inhaled long-acting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma. Cochrane Database Syst. Rev. 2005; 4: CD005533.

22. Ram F.S., Cates C.J. Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. Cochrane Database Syst. Rev. 2006; 4: CD003137.

23. Ni Chroinin M., Greenstone I.R., Ducharme F.M. Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults. Cochrane Database Syst. Rev. 2005; 2: CD005307.

24. Wurthwein G., Render S., Rodhewald P. Lipophility and receptor affinity of glucocorticoids. Pharm Ztg. Wiss. 1992; 5: 2-8.

25. Barnes N.C., Hallett C., Harris T.A. Clinical experience with fluticasone propionate in asthma: a meta-analysis of efficacy and systemic activity compared with budesonide and beclomethasone dipropionate at half the microgram dose or less. Respir. Med. 1998; 92: 95-104.


Для цитирования:

Емельянов А.В., Сергеева Г.Р. Безопасность комбинированной терапии сальметеролом и флутиказона пропионатом у больных бронхиальной астмой. Пульмонология. 2009;(5):107-112.

Просмотров: 139

Creative Commons License
Контент доступен под лицензией Creative Commons Attribution-NonCommercial 4.0 International.

ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)